Payment overview · 2025
General Payments
$25.06
1 reported records · 1 companies
Healthcare provider profile · identity verified
Marina Goikhberg, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STATEN ISLAND, NY · NPI 1013071620
Verified facts
What the public records show
CMS Open Payments records show Marina Goikhberg, MD received $25.06 in general payments during 2025 across 1 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.06 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $25.06 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
147 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 521 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 440 | 103 |
| Losartan Potassium | Losartan Potassium | 437 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 76 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 313 | 59 |
| Sertraline Hcl | Sertraline Hcl | 284 | 43 |
| Famotidine | Famotidine | 283 | 55 |
| Omeprazole | Omeprazole | 269 | 61 |
| Metformin Hcl | Metformin Hcl | 194 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 185 | 46 |
| Gabapentin | Gabapentin | 176 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 46 |
| Tradjenta | Linagliptin | 167 | 21 |
| Nifedipine Er | Nifedipine | 159 | 32 |
| Glipizide | Glipizide | 155 | 25 |
| Ozempic | Semaglutide | 148 | 26 |
| Eliquis | Apixaban | 147 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 24 |
| Carvedilol | Carvedilol | 131 | 21 |
| Glipizide Er | Glipizide | 131 | 25 |
| Furosemide | Furosemide | 129 | 24 |
| Celecoxib | Celecoxib | 126 | 20 |
| Alendronate Sodium | Alendronate Sodium | 118 | 21 |
| Januvia | Sitagliptin Phosphate | 117 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 114 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 104 | 26 |
| Atenolol | Atenolol | 103 | 15 |
| Vascepa | Icosapent Ethyl | 101 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 96 | 16 |
| Lisinopril | Lisinopril | 96 | 18 |
| Meloxicam | Meloxicam | 90 | 27 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 90 | 14 |
| Ammonium Lactate | Ammonium Lactate | 89 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 20 |
| Trulicity | Dulaglutide | 86 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 85 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 19 |
| Enalapril Maleate | Enalapril Maleate | 84 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 77 | 20 |
| Repaglinide | Repaglinide | 75 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | suppressed |
| Clonazepam | Clonazepam | 66 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 65 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | suppressed |
| Creon | Lipase/Protease/Amylase | 58 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | 11 |
| Trazodone Hcl | Trazodone Hcl | 57 | 14 |
| Mounjaro | Tirzepatide | 56 | 14 |
| Alprazolam | Alprazolam | 54 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 45 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Ketoconazole | Ketoconazole | 40 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 40 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | 14 |
| Azithromycin | Azithromycin | 39 | 34 |
| Dexlansoprazole Dr | Dexlansoprazole | 39 | 12 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | suppressed |
| Simvastatin | Simvastatin | 37 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Prednisone | Prednisone | 35 | 30 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 22 |
| Valsartan | Valsartan | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | 11 |
| Zenpep | Lipase/Protease/Amylase | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | 13 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 16 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 11 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 17 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Tacrolimus | Tacrolimus | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Budesonide Er | Budesonide | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cytomel | Liothyronine Sodium | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 11 |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $25.06 · 1 records | PFIZER INC. | NURTEC ODT, ZAVZPRET | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error